Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Total Valuation
Corcept Therapeutics has a market cap or net worth of $3.60B. The enterprise value is $3.49B.
Market Cap$3.60B
Enterprise Value$3.49B
Share Statistics
Corcept Therapeutics has 106,374,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding106,374,020
Owned by Insiders11.88%
Owned by Institutions3.32%
Financial Efficiency
Corcept Therapeutics’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 6.67%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)6.67%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee1.52M
Profits Per Employee196.34K
Employee Count500
Asset Turnover0.91
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of Corcept Therapeutics is 36.3. Corcept Therapeutics’s PEG ratio is -1.22.
PE Ratio36.3
PS Ratio4.75
PB Ratio5.58
Price to Fair Value5.58
Price to FCF25.49
Price to Operating Cash Flow24.77
PEG Ratio-1.22
Income Statement
In the last 12 months, Corcept Therapeutics had revenue of 761.41M and earned 99.65M in profits. Earnings per share was 0.95.
Revenue761.41M
Gross Profit748.43M
Operating Income44.80M
Pretax Income66.46M
Net Income99.65M
EBITDA68.35M
Earnings Per Share (EPS)0.95
Cash Flow
In the last 12 months, operating cash flow was 142.00M and capital expenditures -211.00K, giving a free cash flow of 141.78M billion.
Operating Cash Flow142.00M
Free Cash Flow141.78M
Free Cash Flow per Share1.33
Dividends & Yields
Corcept Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change-39.95%
50-Day Moving Average42.36
200-Day Moving Average66.98
Relative Strength Index (RSI)33.57
Average Volume (3m)1.87M
Important Dates
Corcept Therapeutics upcoming earnings date is May 6, 2026, TBA (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Corcept Therapeutics as a current ratio of 2.92, with Debt / Equity ratio of 0.94%
Current Ratio2.92
Quick Ratio2.85
Debt to Market Cap<0.01
Net Debt to EBITDA-1.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Corcept Therapeutics has paid -33.19M in taxes.
Income Tax-33.19M
Effective Tax Rate-0.50
Enterprise Valuation
Corcept Therapeutics EV to EBITDA ratio is 51.20, with an EV/FCF ratio of 24.69.
EV to Sales4.60
EV to EBITDA51.20
EV to Free Cash Flow24.69
EV to Operating Cash Flow24.65
Balance Sheet
Corcept Therapeutics has $372.15M in cash and marketable securities with $6.11M in debt, giving a net cash position of $366.05M billion.
Cash & Marketable Securities$372.15M
Total Debt$6.11M
Net Cash$366.05M
Net Cash Per Share$3.44
Tangible Book Value Per Share$6.24
Margins
Gross margin is 98.30%, with operating margin of 5.88%, and net profit margin of 13.09%.
Gross Margin98.30%
Operating Margin5.88%
Pretax Margin8.73%
Net Profit Margin13.09%
EBITDA Margin8.98%
EBIT Margin8.73%
Analyst Forecast
The average price target for Corcept Therapeutics is $94.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$94.00
Price Target Upside177.53% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast17.92%
EPS Growth Forecast-26.13%